NCT02382900 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Status UNKNOWN Phase PHASE3
NCT02382406 Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Status TERMINATED Phase PHASE1/PHASE2
NCT02379858 Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair Status TERMINATED Phase NA
NCT02375672 Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer Status COMPLETED Phase PHASE2
NCT02370498 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Status COMPLETED Phase PHASE3
NCT02365766 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects Status COMPLETED Phase PHASE1/PHASE2
NCT02364752 A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344) Status WITHDRAWN Phase PHASE1
NCT02364609 Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Status COMPLETED Phase PHASE1
NCT02364076 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Status UNKNOWN Phase PHASE2
NCT02362997 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Status COMPLETED Phase PHASE2
NCT02362594 Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02362048 ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Status COMPLETED Phase PHASE2
NCT02362035 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Status COMPLETED Phase PHASE1/PHASE2
NCT02358044 Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) Status COMPLETED Phase PHASE3
NCT02358031 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Status COMPLETED Phase PHASE3
NCT02351739 Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer Status COMPLETED Phase PHASE2
NCT02348008 Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: Status COMPLETED Phase PHASE1/PHASE2
NCT02346344 Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus Status COMPLETED Phase N/A